Managing Gout in Patients with Metabolic Syndrome.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
27 Jul 2024
27 Jul 2024
Historique:
accepted:
07
07
2024
medline:
27
7
2024
pubmed:
27
7
2024
entrez:
26
7
2024
Statut:
aheadofprint
Résumé
Gout is characterized by monosodium urate (MSU) crystal deposition secondary to hyperuricemia. Gout is associated with metabolic syndrome (MetS) and its related comorbid conditions such as cardiovascular disease (CVD). Major advances have been made in the comprehension of the link between MetS and gout. Despite observational studies suggesting an association between MetS-related conditions and hyperuricemia, there is no proof of causality. Most studies using Mendelian randomization did not find hyperuricemia as a causal factor for MetS-related conditions. In contrast, these conditions were found associated with hyperuricemia, which suggests a reverse causality. Among patients with gout, this high CVD risk profile implies the need for systematic screening for MetS-related conditions. Most international guidelines recommend systematic screening for and care of CVD and related risk factors in patients with gout. Some anti-hypertensive agents, such as losartan and calcium channel blockers, are able to decrease serum urate (SU) levels. However, there are potential interactions between gout management therapies and the treatment of metabolic diseases. Some data suggest that anti-inflammatory drugs used for gout flare treatment, such as colchicine or canakinumab, might have benefits for CVD. Regarding the impact of urate-lowering therapies on CVD risk, recent studies found a similar CVD safety profile for allopurinol and febuxostat. Finally, sodium-glucose cotransporter-2 inhibitors are promising for gout because of their ability to decrease SU levels and risk of recurrent flares. In this review, we focus on the clinical challenge of managing MetS in patients with gout, particularly older patients with co-medications.
Identifiants
pubmed: 39060816
doi: 10.1007/s40266-024-01132-x
pii: 10.1007/s40266-024-01132-x
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318–28.
pubmed: 19692116
Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78(11):1592–600.
pubmed: 31501138
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of Gout. Arthritis Rheumatol. 2020;72(6):879–95.
pubmed: 32390306
Mandl P, D’Agostino MA, Navarro-Compan V, Gessl I, Sakellariou G, Abhishek A, et al. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice. Ann Rheum Dis. 2024;83(6):752–9.
pubmed: 38320811
Pascart T, Budzik JF. Dual-energy computed tomography in crystalline arthritis: knowns and unknowns. Curr Opin Rheumatol. 2022;34(2):103–10.
pubmed: 35034071
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31–8.
pubmed: 31167758
Leask MP, Merriman TR. The genetic basis of urate control and gout: Insights into molecular pathogenesis from follow-up study of genome-wide association study loci. Best Pract Res Clin Rheumatol. 2021;35(4): 101721.
pubmed: 34732286
Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–62.
pubmed: 26150127
Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991–9.
pubmed: 30618180
pmcid: 6536335
Bardin T, Bouee S, Clerson P, Chales G, Flipo RM, Liote F, et al. Prevalence of Gout in the adult population of France. Arthritis Care Res (Hoboken). 2016;68(2):261–6.
pubmed: 26234279
Bardin T, Magnat E, Clerson P, Richette P, Rouchon B. Epidemiology of gout and hyperuricemia in New Caledonia. Joint Bone Spine. 2022;89(2): 105286.
pubmed: 34601114
Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis. 1997;56(1):22–6.
pubmed: 9059136
pmcid: 1752259
Pascart T, Wasik KA, Preda C, Chune V, Torterat J, Prud’homme N, et al. The gout epidemic in French Polynesia: a modelling study of data from the Ma’i u’u epidemiological survey. Lancet Glob Health. 2024;12(4):e685–96.
pubmed: 38485432
Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T, et al. Global, regional and national burden of gout, 1990–2017: a systematic analysis of the Global Burden of Disease Study. Rheumatology (Oxford). 2020;59(7):1529–38.
pubmed: 31624843
Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109–15.
pubmed: 17266099
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart A, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–8.
pubmed: 14744958
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.
pubmed: 28122885
pmcid: 5408160
Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011–2016. JAMA. 2020;323(24):2526–8.
pubmed: 32573660
pmcid: 7312413
Wiley JF, Carrington MJ. A metabolic syndrome severity score: a tool to quantify cardio-metabolic risk factors. Prev Med. 2016;88:189–95.
pubmed: 27095322
Jung JH, Song GG, Ji JD, Lee YH, Kim JH, Seo YH, et al. Metabolic syndrome: prevalence and risk factors in Korean gout patients. Korean J Intern Med. 2018;33(4):815–22.
pubmed: 27729624
Schlesinger N, Elsaid MI, Rustgi VK. The relationship between metabolic syndrome severity and the risk of mortality in gout patients: a population-based study. Clin Exp Rheumatol. 2022;40(3):631–3.
pubmed: 35238754
Andres M. Gout and Cardiovascular Disease: Mechanisms, Risk Estimations, and the Impact of Therapies. Gout Urate Cryst Depos Dis. 2023;1(3):152–66.
Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894–900.
pubmed: 17698728
Ferguson LD, Molenberghs G, Verbeke G, Rahimi K, Rao S, McInnes IB, et al. Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls. Lancet Rheumatol. 2024;6(3):e156–67.
pubmed: 38383089
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093–103.
pubmed: 15014182
Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008;47(10):1567–70.
pubmed: 18710901
Pan A, Teng GG, Yuan JM, Koh WP. Bidirectional association between self-reported hypertension and gout: the Singapore Chinese health study. PLoS One. 2015;10(10): e0141749.
pubmed: 26510154
pmcid: 4624790
Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(3):335–43.
pubmed: 24281251
pmcid: 4361356
Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177–82.
pubmed: 23313809
Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642–7.
pubmed: 25165032
Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210–7.
pubmed: 25398375
Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat Rev Rheumatol. 2022;18(2):97–111.
pubmed: 34921301
Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11.
pubmed: 32739239
Kim JY, Seo C, Pak H, Lim H, Chang TI. Uric acid and risk of cardiovascular disease and mortality: a longitudinal cohort study. J Korean Med Sci. 2023;38(38): e302.
pubmed: 37750373
pmcid: 10519779
Kim SC, Liu J, Solomon DH. Risk of incident atrial fibrillation in gout: a cohort study. Ann Rheum Dis. 2016;75(8):1473–8.
pubmed: 26324846
Kim J, Lee SY, Lee J, Yoon S, Kim EG, Lee E, et al. Effects of uric acid on ischemic diseases, stratified by lipid levels: a drug-target, nonlinear Mendelian randomization study. Sci Rep. 2024;14(1):1338.
pubmed: 38228698
pmcid: 10791707
Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis. 2013;231(1):61–8.
pubmed: 24125412
Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2014;11(7):1102–8.
pubmed: 24709288
Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, et al. Correlations between serum uric acid and coronary atherosclerosis before and during statin therapy. Coron Artery Dis. 2014;25(4):343–8.
pubmed: 24448173
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(7):885–92.
pubmed: 19565556
pmcid: 2714267
Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102–10.
pubmed: 20824805
pmcid: 3016454
Cicero AF, Rosticci M, Fogacci F, Grandi E, D’Addato S, Borghi C, et al. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. Eur J Intern Med. 2017;37:38–42.
pubmed: 27498274
Viazzi F, Rebora P, Giussani M, Orlando A, Stella A, Antolini L, et al. Increased serum uric acid levels blunt the antihypertensive efficacy of lifestyle modifications in children at cardiovascular risk. Hypertension. 2016;67(5):934–40.
pubmed: 27021006
Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6.
pubmed: 11711505
Mene P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens. 2008;26(11):2085–92.
pubmed: 18854744
Thottam GE, Krasnokutsky S, Pillinger MH. Gout and Metabolic Syndrome: a Tangled Web. Curr Rheumatol Rep. 2017;19(10):60.
pubmed: 28844079
Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30(4):217–26.
pubmed: 22099531
Scheepers LE, Wei FF, Stolarz-Skrzypek K, Malyutina S, Tikhonoff V, Thijs L, et al. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. J Hypertens. 2016;34(11):2147–54.
pubmed: 27607461
Scheepers L, Boonen A, Dagnelie PC, Schram MT, van der Kallen CJH, Henry RMA, et al. Uric acid and blood pressure: exploring the role of uric acid production in The Maastricht Study. J Hypertens. 2017;35(10):1968–75.
pubmed: 28520613
Scheepers LE, Boonen A, Pijnenburg W, Bierau J, Staessen JA, Stehouwer CD, et al. Associations of plasma uric acid and purine metabolites with blood pressure in children: the KOALA Birth Cohort Study. J Hypertens. 2017;35(5):982–93.
pubmed: 28355168
Lyngdoh T, Vuistiner P, Marques-Vidal P, Rousson V, Waeber G, Vollenweider P, et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One. 2012;7(6): e39321.
pubmed: 22723994
pmcid: 3378571
Nitsch D, Molokhia M, Smeeth L, DeStavola BL, Whittaker JC, Leon DA. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol. 2006;163(5):397–403.
pubmed: 16410347
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123.
pubmed: 28669352
pmcid: 5494879
McKeigue PM, Campbell H, Wild S, Vitart V, Hayward C, Rudan I, et al. Bayesian methods for instrumental variable analysis with genetic instruments ('Mendelian randomization’): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. Int J Epidemiol. 2010;39(3):907–18.
pubmed: 20348110
pmcid: 2878456
McCormick N, O’Connor MJ, Yokose C, Merriman TR, Mount DB, Leong A, et al. Assessing the causal relationships between insulin resistance and hyperuricemia and gout using bidirectional mendelian randomization. Arthritis Rheumatol. 2021;73(11):2096–104.
pubmed: 33982892
pmcid: 8568618
Yu X, Wang T, Huang S, Zeng P. Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis. J Hum Genet. 2021;66(5):465–73.
pubmed: 33100326
Rasheed H, Hughes K, Flynn TJ, Merriman TR. Mendelian randomization provides no evidence for a causal role of serum urate in increasing serum triglyceride levels. Circ Cardiovasc Genet. 2014;7(6):830–7.
pubmed: 25249548
pmcid: 4270849
So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639–47.
pubmed: 28959043
Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 1991;34(2):141–5.
pubmed: 1994910
Patetsios P, Song M, Shutze WP, Pappas C, Rodino W, Ramirez JA, et al. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol. 2001;88(2):188–91 (A6).
pubmed: 11448423
Liu-Bryan R, Guo T, Lee J, Terkeltaub R. Atherogenic activation of human vascular smooth muscle cells by monosodium urate crystals. Gout Urate Cryst Depos Dis. 2023;1(3):192–207.
Pascart T, Carpentier P, Choi HK, Norberciak L, Ducoulombier V, Luraschi H, et al. Identification and characterization of peripheral vascular color-coded DECT lesions in gout and non-gout patients: the VASCURATE study. Semin Arthritis Rheum. 2021;51(4):895–902.
pubmed: 34198148
Barazani SH, Chi WW, Pyzik R, Chang H, Jacobi A, O’Donnell T, et al. Quantification of uric acid in vasculature of patients with gout using dual-energy computed tomography. World J Radiol. 2020;12(8):184–94.
pubmed: 32913564
pmcid: 7457162
Dalbeth N, Alhilali M, Riordan P, Narang R, Chhana A, McGlashan S, et al. Vascular deposition of monosodium urate crystals in gout: analysis of cadaveric tissue by dual-energy computed tomography and compensated polarizing light microscopy. Arthritis Rheumatol. 2022;74(7):1295–6.
pubmed: 35023635
Andres M, Mendieta L, Argente-Del-Castillo E, Trigueros M, Minano A, Pascual E. Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia. Joint Bone Spine. 2022;89(5): 105423.
pubmed: 35714832
Pascart T, Budzik JF. Does monosodium urate crystal vascular deposition exist? Review of the evidence. Gout Urate Cryst Depos Dis. 2023;1(3):208–16.
Pascart T, Latourte A, Flipo RM, Chales G, Coblentz-Baumann L, Cohen-Solal A, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy. Joint Bone Spine. 2020;87(5):395–404.
pubmed: 32422338
Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British society for rheumatology guideline for the management of gout. Rheumatology (Oxford). 2017;56(7):1246.
pubmed: 28605531
Group Sw, collaboration ESCCr. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54.
Arts EE, Popa CD, Den Broeder AA, Donders R, Sandoo A, Toms T, et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis. 2016;75(4):674–80.
pubmed: 25691119
Solomon DH, Greenberg J, Curtis JR, Liu M, Farkouh ME, Tsao P, et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. Arthritis Rheumatol. 2015;67(8):1995–2003.
pubmed: 25989470
Andres M, Bernal JA, Sivera F, Quilis N, Carmona L, Vela P, et al. Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. Ann Rheum Dis. 2017;76(7):1263–8.
pubmed: 28093417
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.
pubmed: 31504418
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–232.
pubmed: 30894318
pmcid: 7685565
Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ, et al. Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a case-matched cohort study. PLoS One. 2015;10(12): e0145193.
pubmed: 26683302
pmcid: 4684295
Yen FS, Hsu CC, Li HL, Wei JC, Hwu CM. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. PLoS One. 2020;15(6): e0234909.
pubmed: 32574194
pmcid: 7310696
Dubreuil M, Zhu Y, Zhang Y, Seeger JD, Lu N, Rho YH, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015;74(7):1368–72.
pubmed: 24665118
Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM. Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol. 2011;71(4):600–7.
pubmed: 21395653
pmcid: 3080649
Grimaldi-Bensouda L, Alperovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015;74(5):836–42.
pubmed: 24395556
Singh JA, Ramachandaran R, Yu S, Curtis JR. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovasc Disord. 2017;17(1):76.
pubmed: 28288564
pmcid: 5348884
Kok VC, Horng JT, Chang WS, Hong YF, Chang TH. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PLoS ONE. 2014;9(6): e99102.
pubmed: 24897240
pmcid: 4045898
Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015;128(6):653 (e7- e16).
pmcid: 4442710
Gupta S, Miller E, Stein Merkin S, McMahon M, Watson K, FitzGerald J. The risk of cardiovascular disease among male and female participants treated for gout in the multi-ethnic study of atherosclerosis (MESA). Gout Urate Cryst Depos Dis. 2023. https://doi.org/10.3390/gucdd1020009 .
doi: 10.3390/gucdd1020009
Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10359):1195–205.
pubmed: 36216006
Perez Ruiz F, Richette P, Stack AG, Karra Gurunath R, Garcia de Yebenes MJ, Carmona L. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019;5(2): e001015.
pubmed: 31673414
pmcid: 6803010
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–8.
pubmed: 18975369
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–61.
pubmed: 16339094
Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.
pubmed: 20370912
pmcid: 2888216
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–10.
pubmed: 29527974
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745–57.
pubmed: 33181081
O’Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid. 2022. https://doi.org/10.1056/EVIDoa2100028 .
doi: 10.1056/EVIDoa2100028
pubmed: 35434725
pmcid: 9012032
Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56.
pubmed: 31420554
Latourte A, Pascart T, Flipo RM, Chales G, Coblentz-Baumann L, Cohen-Solal A, et al. 2020 Recommendations from the french society of rheumatology for the management of gout: management of acute flares. Joint Bone Spine. 2020;87(5):387–93.
pubmed: 32422339
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.
pubmed: 31733140
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47.
pubmed: 32865380
Kommu S, Arepally S. The effect of colchicine on atrial fibrillation: a systematic review and meta-analysis. Cureus. 2023;15(2): e35120.
pubmed: 36819949
pmcid: 9937735
Lopez J, Borzak S. In noncardiac thoracic surgery, low-dose colchicine did not reduce AF or myocardial injury after noncardiac surgery at 14 d. Ann Intern Med. 2024;177(1):JC3.
pubmed: 38163371
Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458–64.
pubmed: 22660810
pmcid: 3733459
Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674–9.
pubmed: 26582823
Shah B, Toprover M, Crittenden DB, Jeurling S, Pike VC, Krasnokutsky S, et al. Colchicine use and incident coronary artery disease in male patients with Gout. Can J Cardiol. 2020;36(11):1722–8.
pubmed: 32454073
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.
pubmed: 28845751
Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020;17(9):574–84.
pubmed: 32322101
Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford). 2013;52(1):34–44.
pubmed: 22949727
Loustau C, Rosine N, Forien M, Ottaviani S, Juge PA, Liote F, et al. Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: a multicentre, retrospective study. Joint Bone Spine. 2018;85(6):755–60.
pubmed: 29654950
Ottaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123.
pubmed: 24432362
pmcid: 3978950
Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs. 2011;71(11):1413–39.
pubmed: 21812506
Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–48.
pubmed: 22586173
So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.
pubmed: 17352828
pmcid: 1906806
Yu TF, Gutman AB. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest. 1959;38(8):1298–315.
pubmed: 13673086
pmcid: 442084
Hueskes BA, Roovers EA, Mantel-Teeuwisse AK, Janssens HJ, van de Lisdonk EH, Janssen M. Use of diuretics and the risk of gouty arthritis: a systematic review. Semin Arthritis Rheum. 2012;41(6):879–89.
pubmed: 22221907
Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;12(344): d8190.
Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58(1):2–7.
pubmed: 21632472
Ka T, Inokuchi T, Tsutsumi Z, Takahashi S, Moriwaki Y, Yamamoto T. Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases. Int J Clin Pharmacol Ther. 2006;44(1):22–6.
pubmed: 16425967
Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62(6):572–5.
pubmed: 12759298
pmcid: 1754578
Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol. 2001;28(10):2294–7.
pubmed: 11669172
Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.
pubmed: 26384444
Derosa G, Maffioli P, Reiner Z, Simental-Mendia LE, Sahebkar A. Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis. Drugs. 2016;76(9):947–56.
pubmed: 27260336
Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrom J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411–9.
pubmed: 27009625
Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99.
pubmed: 31382965
pmcid: 6683461
Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172(3):186–94.
pubmed: 31931526
pmcid: 7217750
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
pubmed: 26378978
Zhao SS, Rajasundaram S, Karhunen V, Alam U, Gill D. Sodium-glucose cotransporter 1 inhibition and gout: mendelian randomisation study. Semin Arthritis Rheum. 2022;56: 152058.
pubmed: 35839537
Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–62.
pubmed: 28846182
Banerjee M, Pal R, Mukhopadhyay S. Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis. Acta Diabetol. 2022;59(6):783–91.
pubmed: 35249140
Zhou J, Liu X, Chou OH, Li L, Lee S, Wong WT, et al. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. Rheumatology (Oxford). 2023;62(4):1501–10.
pubmed: 36066415
Yokose C, McCormick N, Abhishek A, Dalbeth N, Pascart T, Liote F, et al. The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout. Nat Rev Rheumatol. 2024;20(4):216–31.
pubmed: 38472344
McCormick N, Yokose C, Wei J, Lu N, Wexler DJ, Avina-Zubieta JA, et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent gout flares and gout-primary emergency department visits and hospitalizations : a general population cohort study. Ann Intern Med. 2023;176(8):1067–80.
pubmed: 37487215
American Diabetes A. Standards of care in diabetes-2023 abridged for primary care providers. Clin Diabetes. 2022;41(1):4–31.